Lupus News

Health care professionals around the world are reporting that the COVID-19 pandemic has prevented patients with systemic lupus erythematosus from receiving optimal care, resulting in increased risk for organ damage, according to a survey.

Patients with rheumatic immune-mediated inflammatory disease who experience myocardial infarction are more likely to die or experience heart failure vs. patients without immune-mediated inflammatory disease, according to data.

Individuals with chronic sleep deprivation demonstrate a higher risk for developing systemic lupus erythematosus, with stronger effects in those with depression and bodily pain, according to data published in Arthritis Care & Research.

Five patients with systemic lupus erythematosus achieved remission after receiving chimeric antigen receptor T-cell therapy, a result that could change the face of treatment for autoimmune conditions, according to researchers.

PHILADELPHIA — A daily glucocorticoid dose higher than 2.5 mg may lead to irreversible bone mineral density loss regardless of intervention with osteoporosis medications, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Among women with systemic lupus erythematosus, just 3.7% are vaccinated for HPV, while nearly 30% demonstrate HPV infection, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Phase 2 findings for the tyrosine kinase 2 inhibitor deucravacitinib yielded encouraging results through 48 weeks in patients with systemic lupus erythematosus, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Among patients with lupus, those with higher copays are more likely to demonstrate poor treatment adherence, according to data presented at ACR Convergence 2022.

PHILADELPHIA – In anti-Ro/La-positive pregnancies, most fetal echocardiography screenings for congenital heart block fail to occur by the recommended time, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Belimumab demonstrated a strong clinical response and significantly reduced flare risk for patients with cutaneous lupus erythematosus, with or without systemic lupus erythematosus, after 20 weeks, said a presenter here.